Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027497 (
nausea
)
23,468
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effect of norethisterone enanthate on clinical and biochemical parameters was studied in 9 normal women aged 21-29 years. Blood samples were taken before and 2, 6, 10, and 14 weeks after injection. Significant changes in serum proteins were observed, as was a significant increase in blood coagulability. Serum triglycerides were significantly lower. Thrombosis and effects on adrenal cortex function and on
glucose
tolerance were not observed. Side effects included breakthrough bleeding,
nausea
, headache, fatigue, nervousness, breast tension, and backache.
...
PMID:[Norethisterone enanthate. Studies during the use of a long-acting parenteral contraceptive]. 535 31
The metabolic response to human growth hormone (HGH) was studied in five obese subjects in the fed state and during prolonged (5-6 wk) starvation. In the fed state (three subjects), HGH induced an elevation in basal serum insulin concentration, a minimal increase in blood and urine ketone levels, and a marked reduction in urinary nitrogen and potassium excretion resulting in positive nitrogen and potassium balance. In prolonged fasting (four subjects), HGH administration resulted in a 2- to 3-fold increase in serum insulin which preceded a 50% elevation in blood
glucose
. Persistence of the lipolytic effects of HGH was indicated by a rise in free fatty acids and glycerol. The response differed markedly from the fed state in that blood beta-hydroxybutyrate and acetoacetate levels rose by 20-40%, resulting in total blood ketone acid concentrations of 10-12 mmoles/liter, ketonuria of 150-320 mmoles/day, and increased urinary potassium loss. The subjects complained of
nausea
, vomiting, weakness, and myalgias. Despite a 50% reduction in urea excretion during HGH administration, total nitrogen loss remained unchanged as urinary ammonia excretion rose by 50% and correlated directly with the degree of ketonuria. It is concluded that in prolonged starvation (a) HGH may have a direct insulinotropic effect on the beta cell independent of alterations in blood
glucose
concentration, (b) persistence of the lipolytic action of HGH results in severe exaggeration of starvation ketosis and interferes with its anticatabolic action by necessitating increased urinary ammonia loss, and (c) failure of HGH to reduce net protein catabolism in starvation suggests that this hormone does not have a prime regulatory role in conserving body protein stores during prolonged fasting.
...
PMID:Metabolic response to human growth hormone during prolonged starvation. 554 Jan 76
28 fertile Belgian women took Ovanon (.08 mg mestranol Days 5-12, .075 mg mestranol and 2.5 mg lynestrenol Days 13-28, 6-day interval) for 337 cycles. Subjects were 18-40 years (mean 25.6), para 1-7 (mean 2), and took Ovanon for 2-25 cycles. There were no pregnancies; 16 pregnanediol tests were 2 mg/24 hours or less; temperature curves all rose just after ingestion of the combined tablet. Menstrual cycles were usually 27-29 days in length, with 3-6 day latency, and 4-5 day flow of normal amount. Trivial side effects reported were
nausea
in 3 patients, spotting in 3 cycles, breakthrough bleeding in 1 cycle, latency of over 7 days in 3 cycles, mucorrhea in 2 patients, headaches causing 1 dropout. 1 woman developed high blood pressure, abnormal
glucose
tolerance, and blood lipid distribution.
...
PMID:[Normal phase method with cyclic administration]. 557 21
Data from 5 studies recently conducted in Bangladesh regarding dizziness as a major side effect of oral contraceptive (OC) use were reviewed. The Bangladeshi women describe dizziness as "Mata gurai" (headspinning), a sensation of rotary motion unaccompanied by
nausea
or vomiting. It appears to mimic the characteristics of postural hypotension rather than true vertigo and is often associated with generalized weakness. Both dizziness and weakness were cited by a large proportion of women in study A as reasons for discontinuation, and the 2 symptoms were often linked. Burning sensations, usually in the extremities, also proved to be a frequent cause of discontinuation. In study B, except for dizziness, there was no significant difference between women continuing OC use and those who had stopped use. The incidence of dizziness reported by discontinuers was significantly higher than that reported by continuing users. The case-control health survey used in study C corroborated the view that some complaints associated with OC use were equally common in nonusers, but the incidence of dizziness and eye problems was significantly higher in OC users than in both matched control groups. There were no significant associations found between dizziness and hemoglobin levels or blood pressure in study D. Of those women who took multiple vitamin capsules in study E, 57% reported a lessening of dizzinesss, compared with 69% who received
glucose
capsules.
...
PMID:Dizziness associated with discontinuation of oral contraceptives in Bangladesh. 610 46
We describe the case of a 10-year-old boy who had been admitted on several occasions with a diagnosis of gastroenteritis. He had been severely ill, and on one occasion lost consciousness. He had a metabolic acidosis on these occasions. Examination of the urine by gas chromatography-mass spectrometry showed a large peak, identified as glycerol. The concentration of glycerol in the urine was 40-280 mmol/L and the concentration in plasma about 2 mmol/L. He was subjected to a fast of 21 h, at the end of which he expressed feelings of discomfort and
nausea
, began vomiting, and became somnolent. During this period the blood
glucose
concentration was only slightly decreased, the plasma glycerol concentration increased to 4.9 mmol/L, and the plasma lactate concentration increased to 3.8 mmol/L. During work on a bicycle ergometer for 35 min (40 W) he complained of muscle pain and became nauseated, but there was no significant increase in the concentration of plasma glycerol. The activity of glycerol kinase (EC 2.7.1.30) in leukocytes and cultured fibroblasts was less than 1% of the value for healthy subjects.
...
PMID:Deficiency of glycerol kinase (EC 2.7.1.30). 629 16
Forty-six pregnant patients with potential diabetes were studied to compare the use of
glucose
and a
glucose
polymer for carbohydrate tolerance testing. The first 26 patients had a
glucose
tolerance test and a
glucose
polymer tolerance test in randomized order an average of one week apart. The mean tolerance curves and insulin curves were similar for both agents. Patients preferred
glucose
polymer to
glucose
because of a lower incidence of associated
nausea
. A second group of 20 patients was randomly divided so that patients had two
glucose
tolerance tests or two
glucose
polymer tolerance tests an average of one week apart. Comparison of the variability and correlation of the incremental areas under the paired tolerance curves showed that the reproducibility of the
glucose
polymer tolerance test exceeded that of the
glucose
tolerance test.
...
PMID:Comparison of glucose and a glucose polymer for testing oral carbohydrate tolerance in pregnancy. 637 52
One hundred women in preterm labor were randomly treated with ritodrine or terbutaline in a double-blind fashion. The drugs were comparably effective during intravenous therapy but, in women with intact membranes, an oral dose of terbutaline, 30 mg daily, was significantly more effective than ritodrine, 120 mg daily, in preventing recurrent labor during a 5-day course of oral therapy (one of 19 versus 12 of 23, p less than 0.001). In women with intact membranes, pregnancy was prolonged 40 +/- 25 days (mean +/- SD) in women receiving terbutaline orally and only 22 +/- 24 days in women receiving ritodrine orally (p less than 0.01). In women with intact membranes, a heart rate greater than or equal to 130 bpm occurred in in a higher proportion of women receiving intravenous treatment with ritodrine than among those receiving terbutaline (20 of 31 versus 8 of 27, p less than 0.05). Terbutaline-treated women, however, were significantly more likely to have a serum
glucose
level in excess of 140 mg/dl than were women treated with ritodrine (13 of 26 versus 6 of 29, p less than 0.05). Side effects commonly observed during intravenous therapy included
nausea
(22%), chest pain (15%), and shortness of breath (15%). Side effects were significantly (p less than 0.025) more likely to occur during periods when the infusion rate was being increased rather than during periods when the infusion rate was constant.
...
PMID:A double-blind study comparing ritodrine and terbutaline in the treatment of preterm labor. 638 45
During 1880 patient-months of treatment with continuous subcutaneous insulin infusion in 101 patients with IDDM, 36 episodes of acute, severe loss of glycemic control, including 29 with significant ketoacidosis, occurred in 20 patients. Fifteen episodes were attributable to failure of insulin delivery to the patient while 13 were precipitated by infection. Insufficiently frequent blood
glucose
monitoring, failure by patients to detect mechanical and technical problems with infusion systems, failure to adhere to "sick day" regimens, and delay in seeking medical help all contributed to the progression of a number of episodes. Thirst,
nausea
, and vomiting were the common clinical manifestations of decompensation; and the degree of acidemia was often mild in relation to the degree of hyperglycemia. Response to conventional management was usually prompt.
...
PMID:Diabetic ketoacidosis during long-term treatment with continuous subcutaneous insulin infusion. 642 52
A case of central pontine myelinolysis (CPM) following rapid correction of hyponatremia was reported and literatures were reviewed. The case was 61-year-old nonalcoholic female who had taken an operation of craniopharyngioma 23 years ago. Fifteen years later, she received re-operation for the recurrent tumor, followed by replacement therapy of corticosteroid and clofibrate. She was otherwise well until two weeks before entry, when she noticed abrupt onset of high grade fever,
nausea
, vomiting and general malaise. She was admitted to an emergency hospital because of weakness, disorientation and a slight impairment of consciousness, but she was able to speak and to take some food per os. Laboratory studies disclosed urinary tract infection and showed a serum sodium level of 117 mEq/l, potassium 2.9 mEq/l, a serum osmolarity 232 mO sm/l and urine osmolarity 141 mEq/l. She was diagnosed to have an exacerbation of adrenal insufficiency with hyponatremia and hypotonic dehydration triggered by urinary tract infection. Intravenous administration of vitamin B complex, electrolytes including KCL, 5%
glucose
solution and physiological saline with a large amount of corticosteroid was performed aggressively. Serum sodium concentration was raised to 161 mEq/l in two days, and the increased level had been maintained more than five days, resulting in coma and flaccid quadriplegia. During this period, there was no episode of hypotension, hypoglycemia, hypoxia nor hepatic failure which could have caused brain damage.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:[Central pontine and extrapontine myelinolysis following rapid correction of hyponatremia--report of an autopsy case]. 646 6
Low dose estrogen tablets, containing less than 50 mcg of ethinyl estradiol, were formulated because of the recognized dose response relationship with the steroid content of the tablet and side effects. These new oral contraceptives (OCs) are as effective as the older high-dose OCs, and available evidence reports fewer side effects. This discussion reviews pharmacology of these new OCs, the mechanism of action, contraindications, side effects, and problems with the low-dose estrogen OC. Ethinyl estradiol is the only estrogen used in the low-dose combination OC. There are several synthetic progestins: norethindrone, norethindrone acetate, norgestrel, levonorgestrel, and ethynodiol diacetate. These progestins have different potencies so the pharmacologic activity cannot be accurately predicted based on the amount present in the tablet. The synthetic steroids in OCs are absorbed in the small intestine, metabolized in the liver, excreted in the bile and feces with a half-life of 24 hours. The low-dose estrogen combination preparation is taken 3 out of every 4 weeks. Its contraceptive effect is primarily a result of hypothalamic mediated gonadotropin suppression with subsequent inhibition of ovulation. Contraindications to taking the low-dose OC are the same as for the higher dose OC: thromboembolic or cardiovascular disease, estrogen dependent neoplasia, markedly impaired liver function, undiagnosed genital bleeding, congenital hyperlipidemia, pregnancy, and women over age 30 who smoke. Relative contraindications include hypertension, diabetes mellitus, migraine headaches, uterine myomas, and epilepsy. The often quoted 2-5-fold increased incidence of thromboembolic disease, myocardial infarction, and stroke is based on large epidemiologic studies involving patients taking the older higher dose OCs. Current data from patients taking the newer low-dose medication demonstrate minimal if any increased incidence of these problems in young women who do not smoke. The low-dose estrogen OCs have minimal effect on lipid levels. Early reports of patients using the low-dose OC have shown little if any increased incidence of hypertension. The low-dose contraceptives have little effect on
glucose
tolerance, and there is no evidence to show an increased incidence of overt diabetes in OC users. There is no evidence that use of the combination OC causes an increase in cancer of the cervix, uterus, or ovaries. Clinical complaints of
nausea
, breast discomfort, chloasma, weight changes, and depression are reduced with the low-dose estrogen preparation. Hypomenorrhea while taking the OC occasionally occurs because the lower dose of estrogen is insufficient to stimulate the endometrial growth in face of the predominant progestin-atrophy effect.
...
PMID:Oral contraceptives in 1984. 649 Mar 38
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>